Vygoris

Vygoris is a UK-based specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies for rare and orphan diseases. The company focuses on high-unmet-need areas, particularly in hematology and dermatology, leveraging a lean, expert-led model to bring specialized products to the UK and European markets. Vygoris is notably partnered with the LFB Group for the commercialization of Voncento, a plasma-derived von Willebrand factor and coagulation factor VIII concentrate used to treat von Willebrand disease and Hemophilia A. Additionally, the company is advancing VGR-001, an orphan-designated topical small molecule currently in clinical development for the treatment of congenital ichthyosis. The leadership team comprises industry veterans with significant experience in the rare disease space, many of whom held senior roles at Shire and Baxalta.